Scholarlink

Objective <p>Bladder cancer (BLCA) is one of the most invasive and malignant tumors in the world, thus leading to the urgent need of an accurate and recognizable biomarker. Several previous research has shown that Transient Receptor Potential Melastatin 4 (TRPM4) plays an important role in measuring vascular fragility and endothelial function. However, the role of TRPM4 in tumor hasn’t been explored.</p> Methods <p>We obtained the clinical data and gene expression profiles of The Cancer Genome Atlas (TCGA) datasets via UCSC Xena. The tumor microenvironment (TME) was also evaluated by the amount of immunomodulators. The role of TRPM4 was demonstrated using the dataset GSE130001 via the website (<a href="http://tisch.comp-genomics.org/">http://tisch.comp-genomics.org/</a>)<i>.</i> We also validated the results of the pathway analysis through the Polymerase Chain Reaction (PCR).</p> Results <p>Patients with higher TRPM4 expression showed better prognosis. We found out that high TRPM4 tended to shape an immuno-stimulatory TME with less T cell exhaustion and lower level of immune overdrive. We demonstrated that TRPM4 could predict the molecular subtype and different therapy options in BLCA. We also found the important influence of TRPM4 in P53 pathway and TNF-a pathway. Last but not least, we developed a prognostic model centered on TRPM4 using ten machine learning algorithms, which showed excellent predictive ability.</p> Conclusion <p>High TRPM4 shapes a more immuno-stimulatory tumor microenvironment and can not only predict the immune phenotypes but also predict the clinical phenotypes in BLCA. High TRPM4 predicts better prognosis. TRPM4 is a potential biomarker in the future for identifying the immunogenicity and immune-therapy probability of BLCA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Transient Receptor Potential Melastatin 4 (TRPM4) is associated with an immuno-stimulatory TME and better prognosis in BLCA

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月20日

查看全文
  • Yiqiang Da,
  • Xuerui Chen,
  • Lanxin Yu,
  • Yunxin Li,
  • Zixu Chen,
  • Yuyue Zhang,
  • Hualin Wang,
  • Zhuang Zhu,
  • Yuan Liu,
  • Yao Geng

摘要

Objective

Bladder cancer (BLCA) is one of the most invasive and malignant tumors in the world, thus leading to the urgent need of an accurate and recognizable biomarker. Several previous research has shown that Transient Receptor Potential Melastatin 4 (TRPM4) plays an important role in measuring vascular fragility and endothelial function. However, the role of TRPM4 in tumor hasn’t been explored.

Methods

We obtained the clinical data and gene expression profiles of The Cancer Genome Atlas (TCGA) datasets via UCSC Xena. The tumor microenvironment (TME) was also evaluated by the amount of immunomodulators. The role of TRPM4 was demonstrated using the dataset GSE130001 via the website (http://tisch.comp-genomics.org/). We also validated the results of the pathway analysis through the Polymerase Chain Reaction (PCR).

Results

Patients with higher TRPM4 expression showed better prognosis. We found out that high TRPM4 tended to shape an immuno-stimulatory TME with less T cell exhaustion and lower level of immune overdrive. We demonstrated that TRPM4 could predict the molecular subtype and different therapy options in BLCA. We also found the important influence of TRPM4 in P53 pathway and TNF-a pathway. Last but not least, we developed a prognostic model centered on TRPM4 using ten machine learning algorithms, which showed excellent predictive ability.

Conclusion

High TRPM4 shapes a more immuno-stimulatory tumor microenvironment and can not only predict the immune phenotypes but also predict the clinical phenotypes in BLCA. High TRPM4 predicts better prognosis. TRPM4 is a potential biomarker in the future for identifying the immunogenicity and immune-therapy probability of BLCA.